Canadian Province Expands Biosimilar Switching, But Patient Group Voices Concerns
British Columbia’s move to switch gastrointestinal patients to biosimilar infliximabs by March 2020 has pleased local industry but upset an originator-backed patients’ group.
You may also be interested in...
Biosimilars Canada president Jim Keon has urged the province of Ontario to follow other Canadian provinces by adopting a biosimilar switching policy for its public drug program, in order to cut costs on biologics and re-invest in the healthcare system.
A joint position statement published by originator-backed bodies the Canadian Association of Gastroenterology and Crohn’s and Colitis Canada has expressed caution over so-called ‘non-medical switching’ of IBD patients from brand biologics to biosimilars.
A body supported by biologic originators has attacked British Columbia’s move to switch Crohn’s and colitis patient to infliximab biosimilars, even though the resulting savings will be invested in patient care.